Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV
Abstract Islatravir (MK‐8591) is a nucleoside analogue in development for the treatment and prevention of HIV‐1. Two phase 1 trials were conducted during initial evaluation of islatravir: rising single doses (Study 1) and rising multiple doses (Study 2) of oral islatravir in male and female particip...
Saved in:
Main Authors: | Randolph P. Matthews (Author), Wendy Ankrom (Author), Evan Friedman (Author), Deanne Jackson Rudd (Author), Yang Liu (Author), Robin Mogg (Author), Deborah Panebianco (Author), Inge De Lepeleire (Author), Magdalena Petkova (Author), Jay A. Grobler (Author), Selwyn Aubrey Stoch (Author), Marian Iwamoto (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
O6 Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least 7 days
by: Inge De Lepeleire, et al.
Published: (2017) -
P2 A single monotherapy dose of MK-8591, a novel NRTI, suppresses HIV for 10 days
by: Martine Robberechts, et al.
Published: (2016) -
Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques
by: Michele B. Daly, et al.
Published: (2023) -
Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters
by: Meika Kaneko, et al.
Published: (2021) -
CaMK II in Cardiovascular Diseases, Especially CaMK II-δ: Friends or Enemies
by: Tan YQ, et al.
Published: (2024)